Sun Pharm moves up on getting nod to manufacture, market semaglutide in Brazil
Sun Pharmaceutical Industries is currently trading at Rs. 2006.25, up by 16.50 points or 0.83% from its previous closing of Rs. 1989.75 on the BSE.
The scrip opened at Rs. 1999.45 and has touched a high and low of Rs. 2,011.15 and Rs. 1989.75 respectively. So far 8779 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 2,011.15 on 30-Jul-2026 and a 52 week low of Rs. 1547.25 on 26-Sep-2025.
Last one week high and low of the scrip stood at Rs. 2,011.15 and Rs. 1,935.00 respectively. The current market cap of the company is Rs. 481762.47 crore.
The promoters holding in the company stood at 54.48%, while Institutions and Non-Institutions held 36.70% and 8.82% respectively.
Sun Pharmaceutical Industries has received approval from the Brazilian Health Regulatory Agency, ANVISA to manufacture and market semaglutide injection in Brazil for the treatment of adults with inadequately controlled type 2 diabetes mellitus as an adjunct to diet and exercise.
The company plans to launch the product in the next few days in partnership with Hypera Pharma, a leading pharmaceutical company in Brazil. It will be available as a pre-filled, multi-dose injectable pen in two strengths (2 mg/1.5 mL and 4 mg/3 mL) allowing flexible, once-weekly dosing. The semaglutide injectable market in Brazil is around $413 million (IQVIA, MAT June 2026).
